Frataxin (F4V2S) Rabbit mAb #64668
- WB
- IHC
Supporting Data
| REACTIVITY | H M |
| SENSITIVITY | Endogenous |
| MW (kDa) | Full-length 23 - Intermediate 17 - Mature 14 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IHC-Immunohistochemistry
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Simple Western™ | 1:10 - 1:50 |
| Immunohistochemistry (Paraffin) | 1:800 - 1:3200 |
Storage
For a carrier free (BSA and azide free) version of this product see product #20892.
Protocol
Specificity / Sensitivity
Frataxin (F4V2S) Rabbit mAb recognizes endogenous levels of total frataxin protein. Species cross-reactivity for IHC-P is human only.
Species Reactivity:
Human, Mouse
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the carboxy terminus of human frataxin protein.
Background
Frataxin is a highly conserved, ubiquitously expressed mitochondrial protein implicated in iron-sulfide cluster (ISC) assembly and iron homeostasis. Synthesized as a cytosolic 210 amino acid precursor protein, frataxin undergoes a two-step proteolytic maturation before translocating to the mitochondria (1). The functions of frataxin in the mitochondria have yet to be fully elucidated, though it has been suggested to be an iron chaperone and activator of persulfide transfer from the cysteine desulfurase NFS1 to the scaffold protein ISCU, which occurs in the early stages of ISC assembly. Proper expression levels of frataxin are vital for cell survival, as is highlighted by the fact that complete loss of this protein is embryonically lethal in mice. In humans, the expansion of GAA repeats in the first intron of the frataxin gene (FXN) results in a reduction in its protein expression levels, leading to the development of Friedreich’s ataxia (FRDA). FRDA is an early-onset neurodegenerative disorder and the most common inherited form of ataxia, affecting 1 in 50,000 people. The downregulation of frataxin in FRDA results in mitochondrial iron and reactive oxygen species (ROS) accumulation, mitochondrial dysfunction, and ferroptosis. Patients with FRDA present with a myriad of symptoms, including gait disturbances, cardiomyopathy, muscle weakness, and increased incidence of diabetes. Individuals with higher GAA repeats exhibit more severe and earlier onset of symptoms (2-4).
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.